MitoQ--a mitochondria-targeted antioxidant.
MitoQ--a mitochondria-targeted antioxidant.
复制标题
DOI：
--
复制
发表时间：
2007-06
期刊：
影响因子：
--
通讯作者：
J. Tauskela
中科院分区：
文献类型：
--
作者：
J. Tauskela
MitoQ是一种口服活性抗氧化剂，具有针对线粒体功能障碍的能力。该药物目前正在由安第斯制药公司开发，用于治疗帕金森氏症和与丙型肝炎病毒感染相关的肝损伤的第二阶段临床试验。MitoQ在经历氧化应激和凋亡性死亡的分离线粒体、细胞和组织的大量研究中显示出令人鼓舞的临床前结果。MitoQ的目的不仅是模拟内源性线粒体抗氧化剂辅酶Q10(CoQ10)的作用，而且以线粒体膜电位依赖的方式将辅酶Q10的抗氧化能力大幅提高到超生理水平。MitoQ是首次进入临床，试图将一种抗氧化剂输送到一个细胞内区域，该区域负责增加潜在有害的活性氧物种的水平。MitoQ的临床试验结果将对线粒体靶向方法的相关性产生重要影响。
MitoQ is an orally active antioxidant that has the ability to target mitochondrial dysfunction. The agent is currently under development by Antipodean Pharmaceuticals Inc in phase II clinical trials for Parkinson's disease and liver damage associated with HCV infection. MitoQ has demonstrated encouraging preclinical results in numerous studies in isolated mitochondria, cells and tissues undergoing oxidative stress and apoptotic death. MitoQ aims to not only mimic the role of the endogenous mitochondrial antioxidant coenzyme Q10 (CoQ10), but also to augment substantially the antioxidant capacity of CoQ to supraphysiological levels in a mitochondrial membrane potential-dependent manner. MitoQ represents the first foray into the clinic in an attempt to deliver an antioxidant to an intracellular region that is responsible for the formation of increased levels of potentially deleterious reactive oxygen species. Results from the clinical trials with MitoQ will have important repercussions on the relevance of a mitochondrial-targeted approach.